SARS-CoV-2 chronological genomic evolution and epidemiology in the Middle East and North Africa (MENA) region as affected by vaccination, conflict and socioeconomical disparities: a population-based cohort study.
COVID-19
health economics
health policy
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
08 09 2022
08 09 2022
Historique:
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
26
1
2023
Statut:
epublish
Résumé
To describe the chronological genomic evolution of SARS-CoV-2 and its impact on public health in the Middle East and North Africa (MENA) region. This study analysed all available SARS-CoV-2 genomic sequences, metadata and rates of COVID-19 infection from the MENA region retrieved from the Global Initiative on Sharing All Influenza Data database from January 2020 to August 2021. Inferential and descriptive statistics were conducted to describe the epidemiology of SARS-CoV-2. Genomic surveillance of SARS-CoV-2 in the MENA region indicated that the variants in January 2020 predominately belonged to the G, GR, GH or O clades and that the most common variant of concern was Alpha. By August 2021, however, the GK clade dominated (57.4% of all sequenced genomes), followed by the G clade (18.7%) and the GR clade (11.6%). In August, the most commonly sequenced variants of concern were Delta in the Middle East region (91%); Alpha (44.3%) followed by Delta (29.7%) and Beta (25.3%) in the North Africa region; and Alpha (88.9%), followed by Delta (10%) in the fragile and conflict-affected regions of MENA. The mean proportion of the variants of concern among the total sequenced samples differed significantly by country (F=1.93, P=0.0112) but not by major MENA region (F=0.14, P=0.27) or by vaccination coverage (F=1.84, P=0.176). This analysis of the genomic surveillance of SARS-CoV-2 provides an essential description the virus evolution and its impact on public health safety in the MENA region. As of August 2021, the Delta variant showed a genomic advantage in the MENA region. The MENA region includes several fragile and conflict-affected countries with extremely low levels of vaccination coverage and little genomic surveillance, which may soon exacerbate the existing health crisis within those countries and globally.
Identifiants
pubmed: 36691215
pii: bmjopen-2022-060775
doi: 10.1136/bmjopen-2022-060775
pmc: PMC9461085
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e060775Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Travel Med Infect Dis. 2020 Sep-Oct;37:101692
pubmed: 32330561
Nat Med. 2021 May;27(5):744-745
pubmed: 33828291
Med (N Y). 2022 Sep 9;3(9):636-643.e4
pubmed: 35981541
PLoS Comput Biol. 2019 Apr 8;15(4):e1006650
pubmed: 30958812
Signal Transduct Target Ther. 2020 Dec 28;5(1):299
pubmed: 33372174
Lancet. 2021 Jun 12;397(10291):2234-2236
pubmed: 33932328
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5813-5818
pubmed: 32495920
JAMA. 2022 Feb 8;327(6):583-584
pubmed: 34967859
Glob Health J. 2021 Mar;5(1):18-23
pubmed: 33585049
Viruses. 2021 Sep 03;13(9):
pubmed: 34578345
Cell Rep. 2022 May 17;39(7):110829
pubmed: 35550680
Sci Rep. 2021 Apr 19;11(1):8435
pubmed: 33875719
Front Psychiatry. 2021 Mar 16;12:633230
pubmed: 33796033
JAMA Netw Open. 2021 Apr 1;4(4):e214347
pubmed: 33822066
Euro Surveill. 2021 Jul;26(28):
pubmed: 34269174
Genome Med. 2014 Nov 20;6(11):90
pubmed: 25422674
Saudi J Biol Sci. 2020 Oct;27(10):2531-2538
pubmed: 32336927
Nucleic Acids Res. 2021 Jul 2;49(W1):W293-W296
pubmed: 33885785
Science. 2020 Jul 31;369(6503):582-587
pubmed: 32513865
J Microbiol Immunol Infect. 2021 Feb;54(1):127-128
pubmed: 32807687
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
BMJ Glob Health. 2021 Jan;6(1):
pubmed: 33419930
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Nat Med. 2021 Sep;27(9):1518-1524
pubmed: 34504335
Sci Rep. 2020 Oct 20;10(1):17720
pubmed: 33082405
J Med Internet Res. 2021 Jan 15;23(1):e25830
pubmed: 33302252
MMWR Morb Mortal Wkly Rep. 2021 Jun 11;70(23):846-850
pubmed: 34111060
J Travel Med. 2021 Oct 11;28(7):
pubmed: 34369565
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056
Sci Data. 2020 Oct 8;7(1):345
pubmed: 33033256